BA
ALXN

Bridgewater Associates’s Alexion Pharmaceuticals ALXN Stock Holding History

Bridgewater Associates’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-4,302
Closed -$790K – 820
2021
Q2 		$790K Sell
4,302
-1,909
-31% -$328K 0.01% 609
2021
Q1 		$950K Sell
6,211
-3,289
-35% -$509K 0.01% 324
2020
Q4 		$1.48M Buy
+9,500
New +$1.22M 0.01% 339
2019
Q4 		– Sell
-475,487
Closed -$46.6M – 586
2019
Q3 		$46.6M Buy
475,487
+445,246
+1,472% +$50.2M 0.41% 27
2019
Q2 		$3.96M Buy
+30,241
New +$3.9M 0.03% 161
2019
Q1 		– Sell
-277,885
Closed -$27.1M – 537
2018
Q4 		$27.1M Buy
+277,885
New +$32.8M 0.25% 50
2018
Q3 		– Sell
-17,053
Closed -$2.12M – 508
2018
Q2 		$2.12M Buy
+17,053
New +$1.99M 0.02% 194
2018
Q1 		– Sell
-65,212
Closed -$7.8M – 499
2017
Q4 		$7.8M Sell
65,212
-52,206
-44% -$6.36M 0.06% 59
2017
Q3 		$16.5M Buy
117,418
+111,020
+1,735% +$15.1M 0.11% 38
2017
Q2 		$778K Sell
6,398
-6,972
-52% -$811K 0.01% 226
2017
Q1 		$1.62M Buy
+13,370
New +$1.72M 0.02% 163
2015
Q2 		– Sell
-29,099
Closed -$5.04M – 413
2015
Q1 		$5.04M Buy
29,099
+10,586
+57% +$1.92M 0.04% 126
2014
Q4 		$3.42M Buy
+18,513
New +$3.43M 0.03% 153
2014
Q3 		– Sell
-26,332
Closed -$4.11M – 434
2014
Q2 		$4.11M Sell
26,332
-24,039
-48% -$3.8M 0.03% 125
2014
Q1 		$7.66M Buy
+50,371
New +$8.01M 0.06% 65

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Bridgewater Associates's ALXN Position: Q3 2021 in Review

Bridgewater Associates sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 4,302 shares — an estimated $790K sold.

Bridgewater Associates first reported a position in ALXN in Q1 2014 and held it in 15 quarters. The position peaked at $46.6M in Q3 2019. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Bridgewater Associates reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Bridgewater Associates sold 4,302 Alexion Pharmaceuticals shares in Q3 2021, an estimated $790K.
  • Bridgewater Associates first reported a position in Alexion Pharmaceuticals in Q1 2014 and held it in 15 quarters.
  • Bridgewater Associates's Alexion Pharmaceuticals position peaked at $46.6M in Q3 2019.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Bridgewater Associates's 13F filing for Q3 2021, filed 12 Nov 2021.